Free Trial
NASDAQ:AVDL

Avadel Pharmaceuticals (AVDL) Stock Price, News & Analysis

Avadel Pharmaceuticals logo
$13.15 -3.15 (-19.33%)
(As of 11/12/2024 ET)

About Avadel Pharmaceuticals Stock (NASDAQ:AVDL)

Key Stats

Today's Range
$12.97
$15.22
50-Day Range
$12.44
$16.30
52-Week Range
$10.25
$19.09
Volume
5.02 million shs
Average Volume
1.17 million shs
Market Capitalization
$1.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.71
Consensus Rating
Buy

Company Overview

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Avadel Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
55th Percentile Overall Score

AVDL MarketRank™: 

Avadel Pharmaceuticals scored higher than 55% of companies evaluated by MarketBeat, and ranked 561st out of 977 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Avadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Avadel Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Avadel Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($0.50) to $0.59 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Avadel Pharmaceuticals is -11.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Avadel Pharmaceuticals is -11.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Avadel Pharmaceuticals has a P/B Ratio of 13.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Avadel Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    9.82% of the outstanding shares of Avadel Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Avadel Pharmaceuticals has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Avadel Pharmaceuticals has recently decreased by 7.26%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Avadel Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Avadel Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.82% of the outstanding shares of Avadel Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Avadel Pharmaceuticals has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Avadel Pharmaceuticals has recently decreased by 7.26%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Avadel Pharmaceuticals has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Avadel Pharmaceuticals this week, compared to 3 articles on an average week.
  • Search Interest

    3 people have searched for AVDL on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Avadel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Avadel Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.80% of the stock of Avadel Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    69.19% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Avadel Pharmaceuticals' insider trading history.
Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVDL Stock News Headlines

Ever heard of this 8-day bitcoin profit window?
Did you know Bitcoin almost always soars higher during an 8-Day Profit Window? Most people have no clue… But for over a year now, some of our top students have had the chance to cash in with some incredible gains during this 8-day window.
Avadel Pharmaceuticals (AVDL) Scheduled to Post Earnings on Tuesday
See More Headlines

AVDL Stock Analysis - Frequently Asked Questions

Avadel Pharmaceuticals' stock was trading at $14.12 at the beginning of 2024. Since then, AVDL shares have decreased by 6.9% and is now trading at $13.15.
View the best growth stocks for 2024 here
.

Avadel Pharmaceuticals plc (NASDAQ:AVDL) issued its quarterly earnings data on Thursday, August, 8th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.03. The business's quarterly revenue was up 2666.7% on a year-over-year basis.

Avadel Pharmaceuticals' top institutional investors include Wealth Effects LLC (2.32%), Modera Wealth Management LLC (0.63%), Iridian Asset Management LLC CT (0.17%) and MAI Capital Management (0.11%). Insiders that own company stock include Gregory J Divis, Eric J Ende, Thomas S Mchugh, Mark Anthony Mccamish, Geoffrey Michael Glass and Linda Palczuk.
View institutional ownership trends
.

Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Avadel Pharmaceuticals investors own include Advanced Micro Devices (AMD), Bank of America (BAC), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Cisco Systems (CSCO) and Netflix (NFLX).

Company Calendar

Last Earnings
8/08/2024
Today
11/12/2024
Next Earnings (Confirmed)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AVDL
Employees
154
Year Founded
2015

Price Target and Rating

Average Stock Price Target
$24.71
High Stock Price Target
$30.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+51.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-160,280,000.00
Net Margins
-111.64%
Pretax Margin
-112.09%

Debt

Sales & Book Value

Annual Sales
$95.15 million
Book Value
$0.98 per share

Miscellaneous

Free Float
91,650,000
Market Cap
$1.57 billion
Optionable
Optionable
Beta
1.47

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:AVDL) was last updated on 11/12/2024 by MarketBeat.com Staff
From Our Partners